Page 55 - Read Online

Saier et al. J Cancer Metastasis Treat 2021;7:43 https://dx.doi.org/10.20517/2394-4722.2021.87 Page 17 of 24

number of studies directly linking bioactive lipid/receptor axes to bone metastasis remains limited, the
constant presence of these lipids in the tumor microenvironment as well as their potent direct activity on
bone cells suggest a still underestimated action of these molecules among the complex integrated molecular
mechanisms responsible for bone metastases progression. Even under the best standard of care, current
targeted bone metastasis therapies are still provided in a palliative purpose with unfortunately no long-term
curative benefit, highlighting the dramatic need for additional strategies. In this context, targeting bioactive
lipids in combination with SPMs may potentially lead to the development of novel therapeutic approaches
that undoubtedly deserve future investigations.

DECLARATIONS
Author’s contributions
Made substantial contributions to writing and correcting the manuscript: Saier L, Niazi H, Brizuela L,
Levkau B, Peyruchaud O

Availability of data and materials
Not applicable.

Financial support and sponsorship
This review was supported by grants from the INSERM (Peyruchaud O), the Université Claude Bernard
Lyon 1 (Peyruchaud O), and the ANR grant BoneTAX (Grant No. ANR-20-CE14-0036-01) (Peyruchaud
O). Saier L was the recipient of a fellowship from the French Ministère de l’Enseignement Supérieur et de la
Recherche. Niazi H was supported by Higher Education Commission of Pakistan. This work was funded in
part by the Else Kröner-Fresenius-Stiftung (Levkau B).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1989;133:571-3. PubMed
2. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93. DOI PubMed
3. Coleman RE, Croucher PI, Padhani AR, et al. Bone metastases. Nat Rev Dis Primers 2020;6:83. DOI PubMed
4. Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 2008;1781:513-8. DOI
PubMed
5. Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res
2014;55:1192-214. DOI PubMed PMC
6. Bektas M, Payne SG, Liu H, Goparaju S, Milstien S, Spiegel S. A novel acylglycerol kinase that produces lysophosphatidic acid
modulates cross talk with EGFR in prostate cancer cells. J Cell Biol 2005;169:801-11. DOI PubMed PMC
7. Tomsig JL, Snyder AH, Berdyshev EV, et al. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular
lysophosphatidic acid in vivo. Biochem J 2009;419:611-8. DOI PubMed PMC
8. Saba JD. Lysophospholipids in development: Miles apart and edging in. J Cell Biochem 2004;92:967-92. DOI PubMed
9. Pagès C, Simon M, Valet P, Saulnier-blache JS. Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat
2001;64:1-10. DOI PubMed
10. van Meeteren LA, Ruurs P, Stortelers C, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation